Otitis Media - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Otitis Media - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Otitis Media - Pipeline Review, H1 2015', provides an overview of the Otitis Media's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Otitis Media
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Otitis Media and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Otitis Media products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Otitis Media pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Otitis Media
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Otitis Media Overview 8
Therapeutics Development 9
Pipeline Products for Otitis Media - Overview 9
Pipeline Products for Otitis Media - Comparative Analysis 10
Otitis Media - Therapeutics under Development by Companies 11
Otitis Media - Therapeutics under Investigation by Universities/Institutes 13
Otitis Media - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Otitis Media - Products under Development by Companies 17
Otitis Media - Products under Investigation by Universities/Institutes 18
Otitis Media - Companies Involved in Therapeutics Development 19
Arbor Pharmaceuticals, LLC. 19
BCO Pharma Ltd 20
Cellceutix Corporation 21
ContraFect Corporation 22
Cubist Pharmaceuticals, Inc. 23
GlaxoSmithKline plc 24
Laboratorios SALVAT S.A. 25
Otonomy, Inc. 26
Serum Institute of India Limited 27
Yuhan Corporation 28
Otitis Media - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
(fluocinolone acetonide + ciprofloxacin hydrochloride) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AR-01 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BCO-002 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
betahistine hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
brilacidin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CF-309 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ciprofloxacin SR - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
GSK-2189242A - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
P-13 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SIILPCV-10 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
solithromycin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
YH-1177 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Otitis Media - Recent Pipeline Updates 55
Otitis Media - Dormant Projects 72
Otitis Media - Product Development Milestones 73
Featured News & Press Releases 73
Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes 73
Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery 74
May 08, 2014: Otonomy Completes Enrollment of AuriPro Pivotal Studies in Pediatric Patients Undergoing Ear Tube Placement Surgery 74
Feb 24, 2014: Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections 75
Dec 11, 2013: Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery 76
Aug 20, 2013: Otonomy Announces Positive Phase 1b Results for OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery 76
May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combination In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes 77
Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections 78
Jun 08, 2011: Otonomy Announces Positive Preclinical Results For OTO-201 79
Dec 30, 2010: 13therapeutics Completes Pre-IND Meeting With FDA 80
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Tables
Number of Products under Development for Otitis Media, H1 2015 9
Number of Products under Development for Otitis Media - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Otitis Media - Pipeline by Arbor Pharmaceuticals, LLC., H1 2015 19
Otitis Media - Pipeline by BCO Pharma Ltd, H1 2015 20
Otitis Media - Pipeline by Cellceutix Corporation, H1 2015 21
Otitis Media - Pipeline by ContraFect Corporation, H1 2015 22
Otitis Media - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 23
Otitis Media - Pipeline by GlaxoSmithKline plc, H1 2015 24
Otitis Media - Pipeline by Laboratorios SALVAT S.A., H1 2015 25
Otitis Media - Pipeline by Otonomy, Inc., H1 2015 26
Otitis Media - Pipeline by Serum Institute of India Limited, H1 2015 27
Otitis Media - Pipeline by Yuhan Corporation, H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Assessment by Combination Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Otitis Media Therapeutics - Recent Pipeline Updates, H1 2015 55
Otitis Media - Dormant Projects, H1 2015 72